



Symposium: Improving Nursing Care and Outcomes for Patients Living with End-Stage Renal Disease

Saturday, 29 July 2017

Chair: Maya N. Clark-Cutaia, PhD, ACNP-BC, RN

Support and Financial Disclosures

1. Sodium-Restricted Diets and Symptoms in End-Stage Renal Disease: A Randomized Controlled Trial
 - NIH-1K23NR015058 (Clark-Cutaia)
2. Nurse-Sensitive Indicators and Patient Transition Safety in Outpatient Hemodialysis Unit
 - American Nephrology Nurses' Association
 - Rutgers University, School of Nursing (Thomas-Hawkins)
3. Stakeholder Perspectives on Care Transition Needs of Patients on Hemodialysis Therapy
 - NewCourtland Center Pilot (Clark-Cutaia & Jarrín)
 - NIH-1K23NR015058 (Clark-Cutaia)
 - AHRQ-K99/R00 HS22406 (Jarrín)

The authors/presenters have disclosed they have no significant relationships with, or financial interest pertaining to the work presented.

Introduction

- An estimated 3.8 million patients are undergoing treatment for end-stage renal disease (ESRD) worldwide.
- Approximately 2 million are undergoing hemodialysis treatment.
- When compared to their counterparts, hemodialysis patients have a higher risk and rate of mortality and reduced life expectancy.



Introduction

- The leading causes of death in this population are cardiovascular disease accounting for 41% of death, 9% infection, 23% from unknown causes and 27% from other causes.
- Lifestyle modification is known to mitigate these risks, but adherence to recommendations is poor (20–78%).
- Given growth in ESRD globally, low adherence to evidence-based practice, and high risk of morbidity and mortality, innovative research is needed to identify and understand the factors unique to the ESRD and hemodialysis experience.

Purpose of Symposium



- Explore patient, provider, and system factors that can be leveraged to decrease adverse events, readmission, and improve symptom management and quality-of-life.
- Dialogue between panel and audience regarding challenges in nursing care and nurse-led innovations for improving care of ESRD and hemodialysis patients.



Symposium Objectives

- Develop a rudimentary understanding of the greatest risk to mortality faced by End-Stage Renal Disease patients.
- Identify current recommendations and restrictions in existing end-stage renal disease treatment modalities.
- Discuss new directions for nursing care of patients with end-stage renal disease.

Sodium-Restricted Diets and Symptoms in End-Stage Renal Disease: A Randomized Controlled Trial

Maya N. Clark-Cutaia, PhD, ACNP-BC
Jamison Fargo, PhD, MS. Epi
Marilyn S. Sommers, PhD, RN, FAAN
Raymond R. Townsend, MD

Background

- Over 600,000 patients in the United States suffer from ESRD¹
- Of those, 468,000 individuals are on dialysis
 - 63.7% receive HD
- Annually, kidney disease kills more people than breast or prostate cancer²
- HD patients have extraordinarily poor outcomes with cardiovascular (CV) death rates greater than 5-times that of non-dialysis patients³ and symptom burdens on-par with cancer patients⁴




Background

- Rehospitalization rates among ESRD patients are twice that of the entire Medicare population¹
- Half of them are related to a primary diagnosis of cardiovascular-related events
 - leading cause of death in ESRD, totaling 54% of deaths with known causes
- Survival at one, two and five years is 77%, 56%, and 42% respectively
- Medicare is the principal payer for ESRD
 - HD Medicare expenditures was \$26.1 billion
 - OR 7.2% of total Medicare expenditures⁵
- These are consistently attributed to the fact that HD is an imperfect replacement for functioning kidneys⁶⁻¹²

Background Cont'd

- Literature indicates that sodium and strict fluid restriction can reduce volume expansion (interdialytic weight gain, IDWG)
 - Reduce morbidity and mortality
- Dietary sodium restriction alone results in a clinically significant reduction of IDWG
 - thereby reducing inter- and intradialytic symptoms⁶⁻¹²
- Average dietary sodium intake similar to that of the general population.¹³⁻²²



Sodium-restricted diets and symptoms in ESRD: An RCT (1K23NR015058-03),

- The Institute of Medicine (IOM) failed to find sufficient evidence of either harm or benefit from sodium restriction at either level of restriction.²⁵
- Minimal empirical evidence behind current sodium intake recommendations and the importance of sodium restriction for HD patients²⁶
- Aim to determine the effects of varying levels of sodium-intake set forth by the National Kidney Foundation and the American Heart Association.
 - Randomized controlled trial to assess the effects of three levels of sodium intake on the HD participant symptom prc
 - Pilot/feasibility study



Sodium-restricted diets and symptoms in ESRD: An RCT (1K23NR015058-03)

Specific Aims.

Aim 1: Demonstrate that symptom and interdialytic weight gain vary among three sodium intake groups, controlling for age, race, gender, and duration of disease.



Sodium-restricted diets and symptoms in ESRD: An RCT (1K23NR015058-03)

Specific Aims.

Aim 2: Demonstrate that the effect of HD-specific variables on the symptom profiles vary among the three sodium intake groups controlling for age, race, gender, and duration of disease.

Aim 3: Determine whether total body water, extracellular fluid, and intracellular fluid measured with bioimpedance spectroscopy vary across sodium intake groups, controlling for age, race, gender, and duration of disease.

Sodium-restricted diets and symptoms in ESRD: An RCT (1K23NR015058-03)



*Design.*²⁶

- We conducted a three-group, double blinded randomized controlled trial with a sample of 42 HD patients.
- Patients were randomized to one of the three groups and admitted to the CHPS for 5 days.
- Baseline/admission data was collected, along with daily surveys, and physiologic measurements.




Results²⁷


Table 1. Baseline Total Sample Descriptive Statistics

Variable	N (%)
Race/Ethnicity	
African American, Black, Afrian, Afro Caribbean: not of Hispanic origin	34 (85.0)
White, Caucasian: not of Hispanic origin	2 (5.0)
Native American, Indian, Alaskan Native	1 (2.5)
Biracial or Multiracial	2 (5.0)
Other	1 (2.5)
Etiology	
Hypertension	18 (45.0)
Diabetes	9 (22.5)
Other	12 (30.0)
Unsure	1 (2.5)
Gender	
Female	19 (47.5)
Male	21 (52.5)
Age	
Under 40	4 (10.0)
40-55	14 (35.0)
56-70	17 (42.5)
>71	5 (12.5)
Perceived General Health	
Excellent	3 (7.5)
Very Good	6 (15.0)
Good	13 (32.5)
Fair	15 (37.5)
Poor	3 (7.5)

Results²⁷



Results²⁷



Conclusions



References

- 1US Renal Data System, USRDS 2015 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2015.
- 2Xu JQ, Murphy SL, Kochanek KD, Bastian BA. Deaths: final data for 2013. www.cdc.gov. Published February 16, 2016. Accessed December 6, 2016.
- 3Dalrymple, LS, Katz, R, Kestenbaum, B, et. al Chronic kidney disease and the risk of end-stage renal disease versus death. *J Gen Intern Med.* (2010); 26(4): 379-385.
- 4Davison, SN, & Jhangri, GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. *J Pain Symptom Manage.* (2010); 39(3): 477-485.
- 5US Renal Data System, USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014.
- 6Menon, V, Sarnak, M. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. *American Journal of Kidney Diseases*; (2005); 45: 223-232.
- 7US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.
- 8Kayikcioglu, M, Tumuklu, M, Ozkahya, M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by hemodialysis. *Nephrology Dialysis Transplant.* (2009): 23:956-962.
- 9Rambod, M, and Ramin T. Dietary Sodium and Clinical Outcome in Hemodialysis: Where Do We Stand and What Is Next? *Kidney International* 82.2 (2012): 130-32. Web.
- 10Causland, Finnian R. Mc, Sushrut S. Waikar, and Steven M. Brunelli. Increased Dietary Sodium Is Independently Associated with Greater Mortality among Prevalent Hemodialysis Patients. *Kidney International* 82.2 (2012): 204-11. Web.
- 11Thomas, M. C, et al. "The Association Between Dietary Sodium Intake, ESRD, and All-Cause Mortality in Patients With Type 1 Diabetes." *Diabetes Care* 34.4 (2011): 861-66. Web.
- 12Bibbins-Domingo, K, Chertow, GM, Coxson, PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. *N Engl J Med* 2010; 362:590–599.
- 13McMahon, EJ, Campbell, KL, Mudge, DW & Bauer, JD. Achieving salt restriction in chronic kidney disease. *International Journal of Nephrology.* (2012); 2012.doi:10.1155/2012/720429.
- 14 Pimenta, E, Gaddam, KK, Oparil, S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension.* (2009); 54(3): 475-481.

References

- 15Luik, PT, Hoogenberg, K, Van der Kleij, FG, et al. Short-term moderate sodium restriction induces relative hyperfiltration in normoalbumenuric Type I Diabetes mellitus. *Diabetologia*. (2002); 45(4):535-541.
- 16Sacks, FM, Svetkey, LP, Vollmer, WM, et al. Effects on blood pressure of reduced dietary sodium and the dietary approached to stop hypertension (dash) diet. *The New England Journal of Medicine*. (2001); 344(1): 3-10.
- 17Todd, AS, Macginley, RJ, Schollum, JB, et al. Dietary salt loading impairs arterial vascular reactivity. *The American Journal of Clinical Nutrition*. (2010); 9(13):557-564.
- 18Gates, PE, Tanaka, H, Hiatt, WR & Seals, DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. *Hypertension*. (2004); 44(1):35-41.
- 19Vogt, L, Waanders, F, Boomsma, F, De Zeeuw, D & Navis, G. Effects pf dietary sodium and hydrochlorothiazide in the antiproteinuric efficacy of losartan. *Journal of the American Society of Nephrology*. (2008); 19(5):999-1007.
- 20Ireland, DM, Clifton, RM, & Keogh, JB. Achieving the salt intake target of 6g/day in the current food supply in the free-living adults using two dietary education strategies. *Journal of the American Dietetic Association*, (2010); 110(5):763-767.
- 21Troyer, JL, Racine, EF, Ngugi, GW & McAuley, WJ. The effect of home-delivered Dietary Approach to Stop Hypertension (DASH) meals on the diets of older adults with cardiovascular disease. *The American Journal of Clinical Nutrition*. (2010); 91(5):1204-1212.
- 22Luis, D, Zlatkis, K, Comenge, K, et. al. Dietary Quality and Adherence to Dietary Recommendations in Patients Undergoing Hemodialysis. *Journal of Renal Nutrition* (2016); 190-95.
- 23Clark-Cutaia, M, Ren, D, Hoffman, L, Burke, LE, Sevick, MA. (2014). Adherence to hemodialysis dietary recommendations: influence of patient characteristics, self-efficacy and perceived barriers. *Journal of Renal Nutrition*; 24(10):92-99.
- 24Clark-Cutaia, M, Sevick, MA, Thurheimer, J, Hoffman, L, Burke, LE, Zickmund, S. Perceived barriers to adherence to hemodialysis dietary recommendations. *Journal of the Academy of Nutrition and Dietetics*.
- 25Institute of Medicine. Sodium intake in populations: Assessment of evidence. Washington, DC: The National Academies Press; 2013.
- 26Clark-Cutaia, M, Sommers, MS, Anderson, E, Townsend, R. (2016). Design of a randomized controlled clinical trial assessing dietary sodium restriction and hemodialysis-related symptom profiles. *Contemporary Clinical Trials Communications*.3: 70-73. doi:10.1016/j.conctc.2-16.04.002.
- 27Clark-Cutaia, M, Townsend, R, Sommers, MS, Fargo, J. Variation in body composition as a result of recommended sodium intake. *Journal of Renal Nutrition*. UNDER REVIEW.